Yousif Capital Management LLC Decreases Stock Position in Incyte Co. (NASDAQ:INCY)

Yousif Capital Management LLC lessened its stake in shares of Incyte Co. (NASDAQ:INCY) by 5.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,109 shares of the biopharmaceutical company’s stock after selling 932 shares during the period. Yousif Capital Management LLC’s holdings in Incyte were worth $1,182,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. R Squared Ltd purchased a new position in Incyte during the 4th quarter valued at approximately $30,000. Brooklyn Investment Group purchased a new position in shares of Incyte in the third quarter valued at $30,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Incyte in the third quarter worth $33,000. Cromwell Holdings LLC raised its stake in Incyte by 101.1% during the third quarter. Cromwell Holdings LLC now owns 563 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 283 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in Incyte by 124.6% during the fourth quarter. Blue Trust Inc. now owns 593 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 329 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Incyte Price Performance

Shares of INCY stock opened at $70.01 on Friday. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. The company has a current ratio of 1.87, a quick ratio of 1.82 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $71.47 and a two-hundred day simple moving average of $69.16. The stock has a market capitalization of $13.49 billion, a price-to-earnings ratio of 500.11, a P/E/G ratio of 0.53 and a beta of 0.70.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. On average, analysts predict that Incyte Co. will post 0.35 EPS for the current fiscal year.

Insider Transactions at Incyte

In other Incyte news, insider Thomas Tray sold 650 shares of Incyte stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $70.64, for a total value of $45,916.00. Following the transaction, the insider now owns 23,962 shares in the company, valued at $1,692,675.68. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven H. Stein sold 12,352 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total transaction of $897,866.88. Following the completion of the transaction, the executive vice president now owns 66,967 shares of the company’s stock, valued at $4,867,831.23. This represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,695 shares of company stock valued at $1,444,356. Company insiders own 17.60% of the company’s stock.

Analysts Set New Price Targets

INCY has been the topic of a number of research reports. Wells Fargo & Company boosted their target price on shares of Incyte from $68.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, December 19th. StockNews.com cut Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. UBS Group initiated coverage on Incyte in a research report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 price objective on the stock. Bank of America raised Incyte from a “neutral” rating to a “buy” rating and boosted their target price for the company from $68.00 to $90.00 in a research report on Tuesday, October 29th. Finally, Oppenheimer raised their price target on Incyte from $81.00 to $82.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $75.59.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.